SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-264740
Filing Date
2020-10-06
Accepted
2020-10-06 16:15:54
Documents
12
Period of Report
2020-10-06
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d18564d8k.htm   iXBRL 8-K 24005
  Complete submission text file 0001193125-20-264740.txt   149262

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20201006.xsd EX-101.SCH 3052
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20201006_lab.xml EX-101.LAB 18908
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20201006_pre.xml EX-101.PRE 11851
5 EXTRACTED XBRL INSTANCE DOCUMENT d18564d8k_htm.xml XML 3490
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 201226935
SIC: 2834 Pharmaceutical Preparations